Systemic Therapy Combined with Locoregional Therapy Improved Survival in Oligometastatic Breast Cancer: A Single-Center Retrospective Cohort Study
Table 1
Demographics and clinical characteristics.
Variable
ST to LRT group
LRT to ST group
ST alone group
value
Age
0.131
Median(range)
43.0 (22-57)
46.5 (28-83)
45.0 (23-70)
ECOG.ps [ (%)]
0.775
0
15 (53.6)
28 (63.6)
69 (54.3)
1
13 (46.4)
16 (36.4)
56 (44.1)
2
0 (0.0)
0 (0.0)
2 (1.6)
Stage at initial diagnosis (UICC 7th) [ (%)]
0.553
I
0 (0.0)
2 (4.5)
7 (5.5)
II
14 (50.0)
23 (52.3)
49 (38.6)
III
12 (42.9)
14 (31.8)
59 (46.5)
Unknown
2 (7.1)
5 (11.4)
12 (9.4)
Pathologic type [ (%)]
0.185
IDC
23 (82.1)
37 (84.1)
114 (89.8)
ILC
2 (7.1)
2 (4.5)
1 (0.8)
Unknown or others
3 (10.7)
5 (11.4)
12 (9.4)
Immunohistochemical subtype [ (%)]
0.058
HR+HER2-
7 (25.0)
18 (40.9)
31 (24.4)
HR+HER2+
11 (39.3)
7 (15.9)
23 (18.1)
HR-HER2+
6 (21.4)
11 (25.0)
30 (23.6)
TNBC
4 (14.3)
5 (11.4)
29 (22.8)
Numbers of metastatic lesions [ (%)]
<0.001
1
11 (39.3)
21 (47.7)
10 (7.9)
2-3
10 (35.7)
10 (22.7)
32 (25.2)
4-5
7 (25.0)
13 (29.5)
85 (66.9)
Metastatic site [ (%)]
Local skin or chest
6 (21.4)
13 (29.5)
22 (17.3)
0.223
Lymph node
11 (39.3)
16 (36.4)
43 (33.9)
0.847
Lung
3 (10.7)
4 (9.1)
45 (35.4)
<0.001
Liver
4 (14.3)
5 (11.4)
32 (25.2)
0.099
Bone
12 (42.9)
11 (25.0)
35 (27.6)
0.215
Others
0 (0.0)
3 (6.8)
6 (4.7)
0.463
Previous neoadjuvant/adjuvant chemotherapy [ (%)]
0.380
Anthracycline alone
10 (35.7)
21 (47.7)
53 (41.7)
Taxane alone
0 (0.0)
2 (4.5)
2 (1.6)
Anthracycline+taxane
10 (35.7)
11 (25.0)
50 (39.4)
None or unknown
8 (28.6)
10 (22.7)
22 (17.3)
Previous adjuvant endocrine therapy [ (%)]
0.232
TAM/TOR
13 (46.4)
21 (47.7)
40 (31.5)
AI
1 (3.6)
3 (6.8)
4 (3.1)
None
14 (50.0)
19 (43.2)
79 (62.2)
Unknown or others
0 (0.0)
1 (2.3)
4 (3.1)
Previous adjuvant anti-HER2 therapy [ (%)]
0.728
Trastuzumab
0 (0.0)
0 (0.0)
3 (2.4)
None or unknown
28 (100)
44 (100)
124 (97.6)
Abbreviations: ST to LRT: systemic therapy followed by locoregional therapy; LRT to ST: locoregional therapy followed by systemic therapy; ST: systemic therapy; ECOG.ps: Eastern Cooperative Oncology Group performance status; UICC 7th: Union for International Cancer Control, the seventh edition; IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; HR: hormone receptor; HER2: human epidermal growth factor receptor 2; TNBC: triple negative breast cancer; TAM: tamoxifen; TOR: toremifene; AI: aromatase inhibitor.
